16 completed, 9 recruiting, 7 unknown, 4 terminated. 19 Not applicable, 11 Phase 2, 4 Phase 3, 1 Early Phase 1, 1 Phase 1.
Follow Treatment-Resistant Depression: new trials by email Literature Review of Treatment-Resistant Depression trials Research Report on Treatment-Resistant Depression
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Evaluating the Role of Psilocybin Monitors in Psilocybin Therapy for Treatment Resistant Depression Psilocybin - Treatment-Resistant Depression | Phase 2 | Recruiting | Centre for Addiction and Mental Health | 40 | 2026-07-03 | 2026-08-21 |
| Stereotactic Radiotherapy Treatment for Treatment-Resistant Depression ZAP-X - Treatment-Resistant Depression, Depressive Disorder | Not applicable | Completed | Capital Medical University | 9 | 2026-01-26 | 2026-08-10 |
| Ultrasound Neuromodulation of Circuits and Negative Valence Systems in Treatment-Resistant Depression Low-intensity focused ultrasound - Treatment-Resistant Depression | Not applicable | Recruiting | Laureate Institute for Brain Research, Inc. | 140 | 2025-09-30 | 2026-03-02 |
| Focused Ultrasound Neuromodulation in Patients With Treatment-Resistant Depression Next Generation Dome Helmet (NGDH) - Treatment-Resistant Depression, Treatment-resistant Depression (TRD) | Not applicable | Recruiting | Sunnybrook Health Sciences Centre | 20 | 2025-07-11 | 2025-08-11 |
| Magnetic Resonance-Guided Focused Ultrasound Bilateral Capsulotomy for the Treatment of Refractory Bipolar Depression ExAblate Neuro 4000 - Treatment-Resistant Depression, Bipolar Depression | Not applicable | Recruiting | Sunnybrook Health Sciences Centre | 10 | 2025-06-25 | 2025-08-06 |
| Physical Activity Program for TRD PA program - MoveU.HappyU - Treatment-resistant Depression, Major Depressive Disorder | Not applicable | Recruiting | Unity Health Toronto | 30 | 2024-09-19 | 2025-04-30 |
| Psilocybin-Assisted Psychotherapy for Treatment-Resistant Depression: Comparing One Versus Two Doses of Psilocybin Single Psychedelic Dose Psilocybin, Two Psychedelic Doses Psilocybin - Major Depressive Disorder, Depression | Phase 2 | Active not recruiting | University Health Network, Toronto | 92 | 2024-02-05 | 2026-07-09 |
| Transcranial Alternating Current Stimulation for Treatment-Resistant Depression transcranial alternating current stimulation (tACS), Sham tACS - Treatment-Resistant Depression | Not applicable | Unknown | Xuanwu Hospital, Beijing | 200 | 2024-02-01 | 2024-01-31 |
| Olfactory and Brain Stimulations in Treatment-resistant Depression Non-invasive brain stimulation protocol (intermittent theta burst protocol (iTBS)) combined with pleasant odors delivered during the iTBS procol., Non-invasive brain stimulation protocol (intermittent theta burst protocol (iTBS)) delivered alone. - Treatment-resistant Depression | Not applicable | Recruiting | Hôpital le Vinatier | 80 | 2024-01-27 | 2025-07-24 |
| Does Psilocybin Require Psychedelic Effects to Treat Depression? Psilocybin 25 mg, Risperidone 1 MG, Placebo - Treatment-resistant Depression | Phase 2 | Completed | Centre for Addiction and Mental Health | 41 | 2023-07-01 | 2026-05-07 |
| pBFS Guided High-dose rTMS Therapy for Treatment-Resistant Depression Active rTMS with short inter-session interval, Sham rTMS with short inter-session interval, Active rTMS with long inter-session interval - Treatment-Resistant Depression | Not applicable | Suspended | Changping Laboratory | 60 | 2023-06-19 | 2026-05-06 |
| A Trial of GH001 in Patients With Treatment-resistant Depression GH001, Placebo - Treatment-resistant Depression | Phase 2 | Completed | GH Research Ireland Limited | 81 | 2023-05-24 | 2025-05-31 |
| Observation of Safety and Tolerability Within 1 Year of the Use of R-ketamine / Placebo in Drug-resistant Depression Treatment-Resistant Depression, Major Depressive Disorder | Completed | Medical University of Gdansk | 3 | 2023-04-21 | 2024-05-29 | |
| Adjuvant Accelerated piTBS for Reducing Suicidal Ideation in TRD Patients piTBS being delivered using the Magstim Rapid2 stimulator - Major Depressive Disorder, Treatment-Resistant Depression | Not applicable | Completed | Tri-Service General Hospital (TSGH) | 100 | 2023-03-29 | 2025-05-13 |
| Study of Efficacy, Safety, Tolerability and Pharmacokinetics of MIJ821 in Participants With Treatment- Resistant Depression (TRD) MIJ821 Subcutaneous Injection 1 mg, MIJ821 Subcutaneous Injection 4 mg, MIJ821 Subcutaneous Injection 10 mg - Treatment-Resistant Depression | Phase 2 | Completed | Novartis Pharmaceuticals | 60 | 2023-03-13 | 2025-04-13 |
| Early Identification of TRD and Construction and Clinical Validation of NTBS Precision Technology non-invasive transcranial deep brain stimulation, Sham stimulation, Motor cortex stimulation - Treatment-Resistant Depression | Not applicable | Unknown | First Affiliated Hospital of Zhejiang University | 400 | 2023-01-01 | 2023-03-21 |
| The Mechanisms of Underlying Accelerated Repetitive Transcranial Magnetic Stimulation for Treatment-resistant Depression active iTBS, sham rTMS - Treatment-resistant Depression | Not applicable | Recruiting | First Affiliated Hospital of Zhejiang University | 60 | 2023-01-01 | 2023-01-13 |
| Cortical Inhibition as a Biomarker of Response in a Comparison of Bilateral Versus Unilateral Accelerated Theta Burst Stimulation for Suicidal Ideation in Treatment-Resistant Depression -COMBAT-SI Accelerated Theta Burst Stimulation - Suicidal Ideation, Treatment-resistant Depression | Not applicable | Recruiting | University of California, San Diego | 76 | 2022-09-02 | 2025-11-05 |
| Dorsomedial Prefrontal Neuromodulation in Treatment-resistant Depression Prolonged intermittent theta burst stimulation (piTBS), 20Hz rTMS, sham control - Treatment-resistant Depression, Major Depressive Disorder | Not applicable | Unknown | Taipei Veterans General Hospital, Taiwan | 75 | 2022-06-07 | 2022-08-17 |
| Low-dose Ketamine Infusion Among Adolescents With Treatment-resistant Depression Midazolam (active placebo), Ketamine and Midazolam (active placebo), Ketamine - Treatment-resistant Depression, Major Depressive Disorder | Phase 4 | Completed | Taipei Veterans General Hospital, Taiwan | 12 | 2022-03-15 | 2025-09-05 |
Showing 20 of 40. Sign in to see all of them.
Depressive Disorder, Treatment-Resistant (40) · Depression (12) · Depressive Disorder, Major (11) · Depressive Disorder (3) · Anhedonia (1) · Bipolar Disorder (1) · Mental Disorders (1) · Mood Disorders (1) · Motor Activity (1) · Suicidal Ideation (1)
Mental Disorders (39) · Mood Disorders (39) · Depressive Disorder (37) · Behavior (14) · Behavioral Symptoms (13) · Bipolar and Related Disorders (1) · Nervous System Diseases (1) · Neurobehavioral Manifestations (1) · Neurologic Manifestations (1) · Pathological Conditions, Signs and Symptoms (1) · Self-Injurious Behavior (1) · Signs and Symptoms (1) · Suicide (1)
Antidepressive Agents (4) · Ketamine (4) · Duloxetine Hydrochloride (3) · Escitalopram (3) · Esketamine (3) · Midazolam (3) · Psilocybin (3) · Sertraline (3) · Deep Brain Stimulation (2) · Anesthetics (1) · Drug Delivery Systems (1) · Electroencephalography (1) · Methoxydimethyltryptamines (1) · Niacinamide (1) · Propofol (1)
Janssen Research & Development, LLC (3) · Centre for Addiction and Mental Health (2) · First Affiliated Hospital of Zhejiang University (2) · Sunnybrook Health Sciences Centre (2) · Taipei Veterans General Hospital, Taiwan (2) · Beijing Pins Medical Co., Ltd (1) · Capital Medical University (1) · Central Institute of Mental Health, Mannheim (1) · Changping Laboratory (1) · Entheon Biomedical Corp. (1) · GH Research Ireland Limited (1) · Hôpital le Vinatier (1) · Laureate Institute for Brain Research, Inc. (1) · London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's (1) · Mclean Hospital (1)
United States (12) · Canada (9) · Germany (6) · France (5) · Poland (5) · Taiwan (5) · China (4) · Spain (4) · Mexico (3) · Belgium (2) · Brazil (2) · Czechia (2) · Argentina (1) · Australia (1) · Austria (1)
Ben Palanca, MD PhD (1) · Carlos A Zarate, M.D. (1) · Chia-yi Wu, PhD (1) · Chih-Ming Cheng, M.D. (1) · David N Lopez-Garza, M.D. (1) · Eva-Lotta Brakemeier, Prof. Dr. (1) · Gang Wang, Medical Doctor (1) · Hesheng Liu, Ph.D. (1) · Hongxing Wang, MD & PhD (1) · Hsin-An Chang, MD (1) · Ishrat Husain, MBBS, MD (1) · Jonathan C Javitt, MD, MPH (1)
PMID 32367114, PMID 32860422, PMID 33128208, PMID 34235612, PMID 34288609, PMID 34510411, PMID 34973081, PMID 35022754, PMID 36273682, PMID 37019044, PMID 38557430, PMID 39428602, PMID 30922101, PMID 31109201, PMID 31290965, PMID 31651355, PMID 32248820, PMID 32270176, PMID 32316080, PMID 32591498, PMID 32871534, PMID 34293233, PMID 34750057, PMID 34971723, PMID 35441931, PMID 35931041, PMID 36149841, PMID 36525338, PMID 37158911, PMID 38025416, PMID 38025433, PMID 38554563, PMID 39435126, PMID 39744036, PMID 40892783, PMID 41245530, PMID 41848690, PMID 41879760, PMID 41922057
2014 (3), 2017 (1), U01MH128483 (1)